Document is current
Any future updates will be listed below
-
Authors
Angelidou, Asimenia https://orcid.org/0000-0002-6716-6561
Koster, Jacob A. https://orcid.org/0000-0002-4645-6308
Sherman, Amy C. https://orcid.org/0000-0002-6075-3990
McLoughlin, Caitlyn https://orcid.org/0009-0001-6559-8539
Lalwani, Pooja
Kelly, Aisling
Saeed, Ahsan
McEnaney, Kerry https://orcid.org/0000-0002-0378-3456
Baden, Lindsey R.
Brogna, Melissa
Weitzman, Elissa R.
Levy, Sharon
Dowling, David J. https://orcid.org/0000-0003-1095-6156
Levy, Ofer https://orcid.org/0000-0002-5859-1945
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038, 75N93020C00038)
- License Information
-
More Information
Article History
Received: 18 July 2024
Accepted: 23 January 2025
First Online: 19 February 2025
Competing interests
: O.L., S.L., and D.J.D. are inventors on patents held by BCH relating to vaccine adjuvants. O.L. is an advisor to GlaxoSmithKline (GSK) and Hillevax and a co-founder of and advisor to OVAX Inc. O.L's laboratory is supported in part by sponsored research from GSK and Pfizer. D.J.D. has served as a consultant for Merck Research Laboratories/Merck Sharp & Dohme Corp. (a Merck & Co. Inc. subsidiary) and is on EdJen BioTech’s scientific advisory board. D.J.D. is a co-founder of OVAX Inc. All other authors declare no competing interests.
